XML 35 R17.htm IDEA: XBRL DOCUMENT
v3.20.1

SHARE-BASED PAYMENTS | 3 Months Ended
--- | ---
Mar. 31, 2020
Share-based Payment Arrangement [Abstract] |
Share-Based Payments | SHARE-BASED PAYMENTS The Company, under the 2018 Amended and Restated Omnibus Equity Incentive Compensation Plan (the “Compensation Plan”), maintains an equity incentive plan for directors, executives, eligible employees and consultants. Equity incentive awards include employee stock options, restricted stock units (“RSUs”) and stock appreciation rights ("SARs"). The Company issues new shares of common stock to satisfy exercises and vesting under all of its equity incentive awards. At March 31, 2020, a total of 11,494,516 Common Shares were authorized for equity incentive plan awards. Employee Stock Options The Company, under the Compensation Plan, may grant options to directors, executives, employees and consultants to purchase Common Shares of the Company. The exercise price of the options is set as the higher of the Company’s closing share price on the day before the grant date or the five-day volume weighted average price. Stock options granted under the Compensation Plan generally vest over a period of two years or more and are generally exercisable over a period of five years from the grant date not to exceed 10 years. The value of each option award is estimated at the grant date using the Black-Scholes Option Valuation Model. There were 0.57 million options granted in the three months ended March 31, 2020 (March 31, 2019 – 0.35 million options). At March 31, 2020, there were 1.96 million options outstanding with 1.60 million options exercisable, at a weighted average exercise price of $2.88 and $3.08 respectively, with a weighted average remaining contractual life of 3.52 years. The fully vested options had no intrinsic value at March 31, 2020. The fair value of the options granted under the Compensation Plan for the three months ended March 31, 2020 was estimated at the date of grant, using the Black-Scholes Option Valuation Model, with the following weighted average assumptions:
Risk-free interest rate | 1.6 | % |
Expected life | 5.0 years |  |
Expected volatility | 61.6 | % | *
Expected dividend yield | — | % |
Weighted average expected life of option | 5.0 years |  |
Weighted average grant date fair value | $0.64 |
* Expected volatility is measured based on the Company’s historical share price volatility over a period equivalent to the expected life of the options. The summary of the Company’s stock options at March 31, 2020 and December 31, 2019, and the changes for the fiscal periods ending on those dates is presented below:
| Range of Exercise Prices |  | Weighted Average Exercise Price |  | Number of Options
Balance, December 31, 2018 | $1.70 - $15.61 |  |  | $ | 3.84 |  |  | 1,732,754 |
Granted | 2.92 |  |  | 2.92 |  |  | 296,450 |
Exercised | 1.70 - 2.92 |  |  | 2.27 |  |  | (54,805 | )
Forfeited | 1.70 - 7.42 |  |  | 3.94 |  |  | (342,866 | )
Expired | 6.97 |  |  | 6.97 |  |  | (144,100 | )
Balance, December 31, 2019 | $1.70 - $15.61 |  |  | $ | 3.43 |  |  | 1,487,433 |
Granted | 1.76 |  |  | 1.76 |  |  | 566,102 |
Exercised | — |  |  | — |  |  | — |
Forfeited | — |  |  | — |  |  | — |
Expired | 4.12 - 5.22 |  |  | 4.40 |  |  | (98,512 | )
Balance, March 31, 2020 | $1.70 - $15.61 |  |  | $ | 2.88 |  |  | 1,955,023 |
A summary of the status and activity of non-vested stock options for the three months ended March 31, 2020 is as follows:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Non-vested December 31, 2019 | 223,381 |  |  | $ | 1.32 |
Granted | 566,102 |  |  | 0.64 |
Vested | (435,973 | ) |  | 0.85 |
Forfeited | — |  |  | — |
Non-vested March 31, 2020 | 353,510 |  |  | $ | 0.82 |
Restricted Stock Units The Company grants RSUs to executives and eligible employees. Awards are determined as a target percentage of base salary and generally vest over periods of three years. Prior to vesting, holders of restricted stock units do not have voting rights. The RSUs are subject to forfeiture risk and other restrictions. Upon vesting, the employee is entitled to receive one share of the Company’s common stock for each RSU for no additional payment. During the three months ended March 31, 2020, the Company's Board of Directors issued 0.74 million RSUs under the Compensation Plan (March 31, 2019 - 0.72 million). A summary of the status and activity of non-vested RSUs at March 31, 2020 is as follows:
| Number of Shares |  | Weighted Average Grant Date Fair Value
Non-vested December 31, 2019 | 1,315,536 |  |  | $ | 2.45 |
Granted | 735,146 |  |  | 1.66 |
Vested | (746,477 | ) |  | 2.46 |
Forfeited | — |  |  | — |
Non-vested March 31, 2020 | 1,304,205 |  |  | $ | 2.01 |
The total intrinsic value and fair value of RSUs that vested and were settled for equity in the three months ended March 31, 2020 was $1.21 million (March 31, 2019 – $2.44 million). Stock Appreciation Rights During the three months ended March 31, 2019, the Company's Board of Directors issued 2.20 million SARs under the Compensation Plan with a fair value of $1.25 per SAR. These SARs are intended to provide additional long-term performance-based equity incentives for the Corporation’s senior management. The SARs are purely performance based, because they only vest upon the achievement of performance goals designed to significantly increase shareholder value. Each SAR outstanding entitles the holder, on exercise, to a payment in cash or shares (at the election of the Company) equal to the difference between the market price of the Common Shares at the time of exercise and $2.92 (the market price at the time of grant) over a five-year period, but vest only upon the achievement of the following performance goals: as to one-third of the SARs granted upon the volume weighted average price (“VWAP”) of the Common Shares on the NYSE American equaling or exceeding $5.00 for any continuous 90-calendar day period; as to an additional one-third of the SARs granted, upon the VWAP of the Common Shares on the NYSE American equaling or exceeding $7.00 for any continuous 90 calendar-day period; and as to the final one-third of the SARs granted, upon the VWAP of the Common Shares on the NYSE American equaling or exceeding $10.00 for any continuous 90 calendar-day period. Further, notwithstanding the foregoing vesting schedule, no SARs may be exercised by the holder for an initial period of one year from the Date of Grant; the date first exercisable being January 22, 2020. The share-based compensation recorded during the three months ended March 31, 2020 was $1.00 million (March 31, 2019 - $1.12 million). At March 31, 2020, there were $0.14 million, $1.68 million and $1.05 million of unrecognized compensation costs related to the unvested stock options, RSU awards and SARs, respectively. These costs are expected to be recognized over a period of approximately two years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration